Oliver Luxxe Assets’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Oliver Luxxe Assets’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-16,949	Closed	-$1.35M	–	199
2022 Q2	$1.35M	Buy	16,949 +894	+6%	+$84.7K	0.4%	81
2022 Q1	$1.69M	Buy	16,055 +547	+4%	+$53.3K	0.43%	87
2021 Q4	$1.67M	Buy	15,508 +1,715	+12%	+$187K	0.42%	92
2021 Q3	$1.51M	Buy	+13,793	New	+$1.43M	0.42%	88
2021 Q2	–	Sell	-19,331	Closed	-$1.78M	–	208
2021 Q1	$1.78M	Buy	19,331 +678	+4%	+$57.2K	0.53%	72
2020 Q4	$1.47M	Sell	18,653 -3,444	-16%	-$256K	0.46%	82
2020 Q3	$1.72M	Sell	22,097 -860	-4%	-$59.2K	0.64%	56
2020 Q2	$1.28M	Buy	+22,957	New	+$982K	0.67%	52

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Oliver Luxxe Assets's HZNP Position: Q3 2022 in Review

Oliver Luxxe Assets sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q3 2022, closing a stake of 16,949 shares — an estimated $1.35M sold.

Oliver Luxxe Assets first reported a position in HZNP in Q2 2020 and held it in 8 quarters. The position peaked at $1.78M in Q1 2021. 530 funds tracked by Wall St. Rank hold HZNP as of Q3 2022.

Oliver Luxxe Assets reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q3 2022 after selling out during the quarter.
Oliver Luxxe Assets sold 16,949 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q3 2022, an estimated $1.35M.
Oliver Luxxe Assets first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2020 and held it in 8 quarters.
Oliver Luxxe Assets's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $1.78M in Q1 2021.
530 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2022.

Based on Oliver Luxxe Assets's 13F filing for Q3 2022, filed 14 Nov 2022.